AI in Cancer Diagnostics Market Size, Share and Trends Analysis
Published estimates for the AI in cancer diagnostics market range from $1.7B to $17.9B by 2032, a 7x spread driven by scope rather than growth.
$1.0B
$2.4B
11.16%
Global
Executive Summary
Published forecasts for AI in cancer diagnostics disagree by a factor of seven. For 2032, estimates run from roughly $1.7 billion to $17.9 billion. That spread is not a disagreement about how fast the technology will be adopted. It is a disagreement about what is being counted.
Narrow definitions, covering software whose cleared indication is the detection or characterisation of cancer, cluster tightly. DelveInsight puts the market at $1.05 billion in 2024 reaching $2.43 billion by 2032 (11.16% CAGR), SNS Insider at $0.96 billion in 2023 reaching $2.46 billion by 2032 (11.0%), and Precedence Research at $0.89 billion in 2022 reaching $2.08 billion by 2032 (9.35%). Three independent houses landing within 15% of each other on the 2032 endpoint is a meaningful signal. Broader definitions diverge sharply: Global Market Insights reports $17.9 billion by 2032 at 29.2% CAGR, but for all of AI in oncology, with treatment planning, trial matching and clinical workflow included rather than diagnostics alone.
This report adopts the narrow definition and uses DelveInsight's endpoints as its spine, because that definition is the one that can be checked against something countable: regulatory authorisations. The FDA's AI-enabled device list is public. It records 1,524 authorised devices through Q1 2026, of which 1,164, or 76%, are radiology. Annual authorisations have risen from 221 in 2023 to 253 in 2024 to roughly 295 in 2025, with 92 in Q1 2026 alone. That is unit growth in the high teens against low-double-digit revenue growth in the narrow forecasts, which implies falling average revenue per cleared device. The reading is a market where clearance is becoming a commodity and differentiation is moving elsewhere.
The structural conclusion follows from the 76%. AI in cancer diagnostics is, in practice, largely imaging. Computational pathology is where the regulatory firsts have happened, with Paige holding a De Novo authorisation for AI-assisted prostate cancer detection and PathAI receiving 510(k) clearance for AISight Dx in June 2025, but imaging remains the volume. Consolidation has begun: Tempus acquired Paige in August 2025 for $81.25 million, largely in stock, a modest figure for the holder of the category's landmark authorisation.
Key Highlights
Published 2032 estimates span $1.7B to $17.9B, a 7x range driven by scope definition rather than disagreement over growth
Three independent houses (DelveInsight, SNS Insider, Precedence) land within 15% of each other on a narrow definition, clustering at $2.0-2.5B by 2032
The FDA has authorised 1,524 AI-enabled devices through Q1 2026; 1,164 (76%) are radiology, so this market is in practice largely imaging
Authorisations grew from 221 (2023) to 253 (2024) to about 295 (2025), unit growth in the high teens against low-double-digit revenue growth
That gap implies falling revenue per cleared device: regulatory access is commoditising faster than the market is growing
Tempus acquired Paige for $81.25M in August 2025, a modest price for the holder of the category's De Novo authorisation
The absence of a durable reimbursement pathway is the main reason conservative estimates have held
Market Overview
Market Context
Cancer diagnosis is a pattern-recognition problem performed under a workforce constraint. Radiology and pathology both face rising case volumes against a roughly flat supply of specialists. That is the condition under which assistive software gets adopted, regardless of whether it is strictly better than a human reader. The constraint also explains why authorisations cluster so heavily in radiology. Imaging produces standardised digital output at scale, which is what supervised learning requires. Pathology has had to digitise first, since whole-slide imaging is a precondition rather than a feature, which is why its regulatory milestones arrived later and remain fewer. The commercial question is therefore not whether these tools work. It is who captures the value once clearance is no longer scarce.
The AI in cancer diagnostics market is estimated at $1.05 billion in 2024, projected to reach $2.43 billion by 2032 at an 11.16% CAGR on a narrow definition covering software cleared for cancer detection and characterisation. Broader definitions that include treatment planning and workflow reach $17.9 billion over the same period.
Market Stage
Early growth, with regulatory access commoditising faster than revenue
Adoption Level
Established in imaging workflows; earlier in digital pathology
Key Trends
Market Forecast & Data
Base Year (2024)
$1.0B
Forecast (2032)
$2.4B
CAGR (2025-2032)
11.16%
| Year | Market size ($ Billion) |
|---|---|
| 2024Base year | $1.05B |
| 2025 | $1.17B |
| 2026 | $1.30B |
| 2027 | $1.44B |
| 2028 | $1.60B |
| 2029 | $1.78B |
| 2030 | $1.98B |
| 2031 | $2.20B |
| 2032 | $2.43B |
The curve shown here is modelled at a constant 11.16% CAGR between DelveInsight's published 2024 and 2032 endpoints. It is deliberately not presented as a year-by-year prediction. No published source discloses annual figures for this market, and inventing inflection points would imply knowledge that does not exist. What can be said about the shape comes from the authorisation data. Device clearances grew roughly 14% from 2023 to 2024 and 17% from 2024 to 2025, and Q1 2026 alone added 92. If unit growth continues to outpace revenue growth, the implication is price compression rather than a demand inflection: more cleared products competing for a market growing more slowly than the supply of them. The principal risk to the low estimates is reimbursement. Diagnostic AI has largely been sold into capital or operating budgets rather than billed per use. A durable reimbursement pathway would break the narrow forecasts upward and move the market toward the broader definitions. Its absence is the single largest reason the conservative estimates have held.
Market Dynamics
- Rising case volumes against a flat supply of radiologists and pathologists
- Standardised digital imaging output, the precondition supervised learning requires
- A widening base of cleared products lowering the barrier to procurement
- Whole-slide imaging adoption opening pathology to computational tools
Market Segmentation
| Segment | Share |
|---|---|
| Radiology and medical imaging1,164 of 1,524 FDA-authorised AI-enabled devices through Q1 2026. The volume of the market, and the reason AI in cancer diagnostics is in practice largely imaging. | 76.0% |
| All other specialties combinedIncludes computational pathology, cardiology, neurology and others. Pathology holds the category's landmark authorisations despite smaller unit counts. | 24.0% |
| Total | 100.0% |
Competitive Landscape
Tempus AI
United States
Acquired Paige in August 2025 for $81.25 million, largely in stock, taking ownership of the category's De Novo prostate authorisation. Launched Paige Predict, covering predictions across 123 molecular biomarkers in 16 cancer types.
Paige
United States
Holder of the landmark De Novo authorisation for AI-assisted prostate cancer detection in pathology, plus Breakthrough Device Designations for Paige Breast Lymph Node and Paige PanCancer Detect.
PathAI
United States
Received FDA 510(k) clearance for AISight Dx in June 2025, extending digital pathology tooling toward clinical diagnostic use.
Recent Developments
AI-enabled device list reaches 1,524 authorisations, 1,164 of them radiology, after 92 new authorisations in Q1 2026.
Acquired Paige for $81.25 million, largely in stock, consolidating the holder of the category's landmark pathology authorisation.
Received FDA 510(k) clearance for AISight Dx in June 2025.
Approximately 295 AI-enabled device clearances from 221 manufacturers, up from 253 in 2024 and 221 in 2023.
Regulatory Landscape
Research Methodology
Primary research
- No primary interviews were conducted for this edition. This report is a synthesis of public sources and is labelled as such rather than implying fieldwork that did not occur.
Secondary research
- FDA AI-Enabled Medical Device List: counts through Q1 2026 (1,524 total, 1,164 radiology, 92 authorised in Q1 2026)
- Published market estimates from DelveInsight (2025), SNS Insider (January 2025), Precedence Research, Allied Market Research and Global Market Insights
- Company announcements and trade reporting on the Tempus-Paige transaction (August 2025) and the PathAI AISight Dx clearance (June 2025)
Validation: Market size is taken from DelveInsight's published 2024 and 2032 endpoints; intermediate years are modelled at a constant 11.16% CAGR and are presented as a modelled curve rather than observed annual data. Where published estimates diverge, the range is reported rather than averaged, and the cause of divergence is stated. Segmentation uses the FDA specialty split because it is countable. No regional or country breakdown is published for this market at a defensible level of confidence, so those sections are omitted rather than estimated. The FDA notes that its list is not a comprehensive resource of AI-enabled medical devices, so unit counts are a floor.
Strategic Takeaways
treat any single headline figure for this market as unusable without its scope definition, since the 7x spread is definitional. Reimbursement policy, not model accuracy, is the variable that would re-rate the sector.
FDA clearance is no longer a differentiator at roughly 295 authorisations a year. Defensibility is shifting to distribution, integration with incumbent PACS and LIS estates, and evidence that supports a billable claim.
the 76% radiology concentration means imaging AI procurement is a mature buy with many substitutes, while pathology AI remains a thinner market gated on whole-slide imaging capital spend.
the Tempus-Paige price of $81.25M against the category's landmark authorisation is the clearest available signal of how this market prices regulatory position versus distribution.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Life SciencesAntimicrobial Resistance Diagnostics Market$5.3B · 6.26% CAGR
- Life SciencesVeterinary Diagnostics Market$9.5B · 9.57% CAGR
- Medical DevicesPoint-of-Care Diagnostics Market$35.2B · 7% CAGR
- BiotechnologyBiotech Personalized Cancer Immunotherapies$124.1B · 11.1% CAGR
- Medical ImagingGlobal Medical Imaging AI Market$1.4B · 22.5% CAGR
- Medical ImagingGlobal United States Medical Imaging AI Market$1.1B · 27.5% CAGR